A team of faculty and fellows from the Molecular Imaging and Therapeutics (MI&T) section at the UC San Francisco Department of Radiology and Biomedical Imaging recently wrote a review on dosimetry in radionuclide therapy for a high-impact journal.
Radionuclide therapy is a rapidly expanding cancer treatment method and type of radiation therapy in which a radionuclide (radioactive chemical) is linked to a cell-targeting molecule, such as a monoclonal antibody, and injected into the body. From there, the cell-targeting molecule binds to a specific target found on some cancer cells. It’s often used to treat prostate cancer, thyroid cancer, metastatic neuroendocrine tumors (NETs) and other types of cancer because it may help kill targeted cancer cells while also limiting harm to normal cells.
In clinical practice, the application of radionuclide therapy relies on fixed or…
